keyword
MENU ▼
Read by QxMD icon Read
search

Transarterial Chemoembolization

keyword
https://www.readbyqxmd.com/read/28643982/-current-surgical-treatment-for-hepatocellular-carcinoma-critical-appraisal-of-current-guidelines
#1
Daniel Clerc, Nermin Halkic, Nicolas Demartines, Emmanuel Melloul
Hepatocellular carcinoma (HCC) management has evolved in the last decades. Current available treatments include interventional radiology like radiofrequency ablation, transarterial chemoembolization or Yttrium 90 radioembolization. Surgery, when possible, has been proven to be the most effective treatment in reducing the risk of long-term local recurrence. American and European societies (AASLD, EASL, respectively) guidelines for the management of HCC endorse The Barcelona Clinic Liver Cancer (BCLC) treatment allocation system...
June 14, 2017: Revue Médicale Suisse
https://www.readbyqxmd.com/read/28643457/eradication-of-hepatitis-c-virus-profoundly-prolongs-survival-in-hepatocellular-carcinoma-patients-receiving-transarterial-chemoembolization
#2
Wei Teng, Yi-Chung Hsieh, Kar-Wai Lui, Wei-Ting Chen, Chien-Fu Hung, Chien-Hao Huang, Yi-Cheng Chen, Wen-Juei Jeng, Chen-Chun Lin, Chun-Yen Lin, Shi-Ming Lin, I-Shyan Sheen
Adjuvant pegylated interferon plus ribavirin treatment (PegIFN/RBV) reduces recurrence and prolongs survival in early stage hepatocellular carcinoma (HCC) patients with chronic hepatitis C (CHC) infection receiving resection or ablation. However, the impact of antiviral therapy in intermediate and advanced stage of CHC-HCC patients is uncertain. This study aimed to investigate the impact PegIFN/RBV treatment on recurrence free interval and survival in HCC patients receiving transarterial chemoembolization (TACE) METHODS: From 2010 to 2013, 274 CHC patients from a 1073-patients based cohort composed of freshly diagnosed HCC and receiving TACE treatment the Chang Gung Memorial Hospital, Linkou Medical Center were recruited...
June 22, 2017: Journal of Viral Hepatitis
https://www.readbyqxmd.com/read/28640364/a-phase-2-study-of-the-efficacy-and-biomarker-on-the-combination-of-transarterial-chemoembolization-and-axitinib-in-the-treatment-of-inoperable-hepatocellular-carcinoma
#3
Stephen L Chan, Winnie Yeo, Frankie Mo, Anthony W H Chan, Jane Koh, Leung Li, Edwin P Hui, Charing C N Chong, Paul B S Lai, Tony S K Mok, Simon C H Yu
BACKGROUND: A surge of vascular endothelial growth factor (VEGF) after transarterial chemoembolization (TACE) may contribute to tumor progression. Axitinib is a potent antiangiogenic agent with main activity against VEGF receptors 1 to 3. To the authors' knowledge, its role in combination with TACE for the treatment of patients with inoperable hepatocellular carcinoma (HCC) is unclear. METHODS: A phase 2 clinical trial (ClinicalTrials.gov identifier NCT01352728) was conducted to evaluate the combination treatment...
June 22, 2017: Cancer
https://www.readbyqxmd.com/read/28636427/liver-directed-therapy-in-metastatic-colorectal-cancer
#4
Ciara M Kelly, Nancy E Kemeny
Colorectal cancer is a significant global health issue with over 1 million cases diagnosed annually throughout the world. 15% of patients diagnosed with colorectal cancer will have liver metastases and 60% will develop liver metastases if they have metastatic disease. Oligometastatic colorectal cancer confined to the liver represents an intermediate state in the evolution of metastatic capacity that opens the opportunity for local interventions. Area's covered: The literature supports long-term survival if patients undergo liver resection of colorectal metastases...
June 21, 2017: Expert Review of Anticancer Therapy
https://www.readbyqxmd.com/read/28634838/superselective-transarterial-chemoembolization-as-an-alternative-to-surgery-in-symptomatic-enlarging-liver-hemangiomas
#5
İlgin Özden, Arzu Poyanlı, Yılmaz Önal, Ali Aslan Demir, Gültekin Hoş, Bülent Acunaş
BACKGROUND: Transarterial embolization of liver hemangiomas has not been considered to be consistently effective. METHODS: The charts of 25 patients who underwent superselective transarterial chemoembolization with the bleomycin-lipiodol emulsion were evaluated retrospectively. RESULTS: Twenty-two patients had abdominal pain; asymptomatic/vaguely symptomatic enlargement was the treatment indication in three patients. A single session was conducted in 17 patients, two sessions in 7 and three sessions in one...
June 20, 2017: World Journal of Surgery
https://www.readbyqxmd.com/read/28634515/transarterial-chemoembolization-using-40-%C3%A2%C2%B5m-drug-eluting-beads-for-hepatocellular-carcinoma
#6
Giorgio Greco, Tommaso Cascella, Antonio Facciorusso, Roberto Nani, Rodolfo Lanocita, Carlo Morosi, Marta Vaiani, Giuseppina Calareso, Francesca G Greco, Antonio Ragnanese, Marco A Bongini, Alfonso V Marchianò, Vincenzo Mazzaferro, Carlo Spreafico
AIM: To assess the safety and efficacy of transarterial chemoembolization (TACE) of hepatocellular carcinoma (HCC) using a new generation of 40 μm drug eluting beads in patients not eligible for curative treatment. METHODS: Drug eluting bead TACE (DEB-TACE) using a new generation of microspheres (embozene tandem, 40 μm) preloaded with 100 mg of doxorubicin was performed on 48 early or intermediate HCC patients with compensated cirrhosis. Response to therapy was assessed with Response Evaluation Criteria in Solid Tumors (RECIST) and modified RECIST (mRECIST) guidelines applied to computed tomography or magnetic resonance imaging...
May 28, 2017: World Journal of Radiology
https://www.readbyqxmd.com/read/28629564/computed-tomography-perfusion-imaging-for-monitoring-transarterial-chemoembolization-of-hepatocellular-carcinoma
#7
Herman P Marquez, Amar Karalli, Holger Haubenreisser, Rishi P Mathew, Hatem Alkadhi, Torkel B Brismar, Thomas Henzler, Michael A Fischer
PURPOSE: To prospectively monitor changes in tumor perfusion of hepatocellular carcinoma (HCC) in response to doxorubicin-eluted bead based transarterial chemoembolization (DEB-TACE) using perfusion-CT (P-CT). METHODS AND MATERIALS: 24 patients (54-79 years) undergoing P-CT before and shortly after DEB-TACE of HCC were prospectively included in this dual-center study. Two readers determined arterial-liver-perfusion (ALP, mL/min/100mL), portal-venous-perfusion (PLP, mL/min/100mL) and the hepatic-perfusion-index (HPI, %) by placing matched regions-of-interests within each HCC before and after DEB-TACE...
June 2017: European Journal of Radiology
https://www.readbyqxmd.com/read/28628947/meta-analysis-of-determinants-of-survival-following-treatment-of-recurrent-hepatocellular-carcinoma
#8
REVIEW
S Erridge, P H Pucher, S R Markar, G Malietzis, T Athanasiou, A Darzi, M H Sodergren, L R Jiao
BACKGROUND: Intrahepatic recurrence of hepatocellular carcinoma (HCC) following resection is common. However, no current consensus guidelines exist to inform management decisions in these patients. Systematic review and meta-analysis of survival following different treatment modalities may allow improved treatment selection. This review aimed to identify the optimum treatment strategies for HCC recurrence. METHODS: A systematic review, up to September 2016, was conducted in accordance with MOOSE guidelines...
June 19, 2017: British Journal of Surgery
https://www.readbyqxmd.com/read/28626733/the-overall-survival-of-patients-with-hepatocellular-carcinoma-correlates-with-the-newly-defined-time-to-progression-after-transarterial-chemoembolization
#9
Tadaaki Arizumi, Kazuomi Ueshima, Mina Iwanishi, Tomohiro Minami, Hirokazu Chishina, Masashi Kono, Masahiro Takita, Norihisa Yada, Satoru Hagiwara, Yasunori Minami, Hiroshi Ida, Yoriaki Komeda, Mamoru Takenaka, Toshiharu Sakurai, Tomohiro Watanabe, Naoshi Nishida, Masatoshi Kudo
AIM/BACKGROUND: The ultimate aim of any treatment for hepatocellular carcinoma (HCC) is to improve overall survival (OS); however, the clinical significance of time to progression (TTP) after transarterial chemoembolization (TACE) is unclear. This retrospective study examined the association between OS and the newly defined time to TACE progression (TTTP) to assess whether TTTP can be an alternative to OS in HCC patients with Barcelona Clinic Liver Cancer (BCLC) stage B. METHODS: Between January 2006 and December 2013, 592 patients with HCC (BCLC B1, n = 118; BCLC B2, n = 170) underwent TACE...
June 2017: Liver Cancer
https://www.readbyqxmd.com/read/28624027/racial-disparities-in-treatment-and-survival-of-hepatocellular-carcinoma-in-native-americans-and-hispanics
#10
Eyas Alkhalili, Alissa Greenbaum, Li Luo, Rodrigo Rodriguez, Oscar Estrada Munoz, Jacqueline O'Neill, Itzhak Nir, Katherine T Morris
BACKGROUND: We investigated if there were any differences in disease presentation and survival between the 3 major ethnicities in New Mexico; non-Hispanic whites (NHW), native Americans (NA), and Hispanics (H). METHODS: A retrospective analysis of patients with hepatocellular carcinoma treated at our institution between 2000 and 2014 was performed. Overall survival was analyzed using the Kaplan-Meier and Cox regression models. RESULTS: We identified 326 patients; 106 (32...
July 2017: American Journal of Surgery
https://www.readbyqxmd.com/read/28618075/surgical-treatment-for-advanced-hepatocellular-carcinoma-with-portal-vein-tumor-thrombus
#11
REVIEW
Kazuhiko Sakamoto, Hiroaki Nagano
The Barcelona Clinic Liver Cancer (BCLC) staging system recommends administration of a tyrosine kinase inhibitor (sorafenib) as standard therapy in advanced hepatocellular carcinoma (HCC) patients with portal vein tumor thrombus (PVTT). Sorafenib has been shown to prolong median overall survival (OS) by about 3 months in advanced HCC patients with PVTT (8.1 vs 4.9 months). However, its clinical effectiveness is still controversial and standard treatment with sorafenib is not established in Japan. Surgical resection is considered as a potentially curative treatment and provides an acceptable outcome for carefully selected patients...
June 15, 2017: Hepatology Research: the Official Journal of the Japan Society of Hepatology
https://www.readbyqxmd.com/read/28617447/targeting-the-vasculature-in-hepatocellular-carcinoma-treatment-starving-versus-normalizing-blood-supply
#12
Ken Liu, Xiang Zhang, Weiqi Xu, Jinbiao Chen, Jun Yu, Jennifer R Gamble, Geoffrey W McCaughan
Traditional treatments for intermediate or advanced stage hepatocellular carcinoma (HCC) such as transarterial chemoembolization (TACE) and anti-angiogenesis therapies were developed to starve tumor blood supply. A new approach of normalizing structurally and functionally abnormal tumor vasculature is emerging. While TACE improves survival in selected patients, the resulting tumor hypoxia stimulates proliferation, angiogenesis, treatment resistance and metastasis, which limits its overall efficacy. Vessel normalization decreases hypoxia and improves anti-tumor immune infiltrate and drug delivery...
June 15, 2017: Clinical and Translational Gastroenterology
https://www.readbyqxmd.com/read/28611522/radiological-response-and-inflammation-scores-predict-tumour-recurrence-in-patients-treated-with-transarterial-chemoembolization-before-liver-transplantation
#13
Daniele Nicolini, Andrea Agostini, Roberto Montalti, Federico Mocchegiani, Cinzia Mincarelli, Alessandra Mandolesi, Nicola L Robertson, Roberto Candelari, Andrea Giovagnoni, Marco Vivarelli
AIM: To investigate the prognostic value of the radiological response after transarterial chemoembolization (TACE) and inflammatory markers in patients affected by hepatocellular carcinoma (HCC) awaiting liver transplantation (LT). METHODS: We retrospectively evaluated the preoperative predictors of HCC recurrence in 70 patients treated with conventional (n = 16) or doxorubicin-eluting bead TACE (n = 54) before LT. The patient and tumour characteristics, including the static and dynamic alpha-fetoprotein, neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio (PLR) measurements, were recorded...
May 28, 2017: World Journal of Gastroenterology: WJG
https://www.readbyqxmd.com/read/28608003/transarterial-chemoembolization-for-management-of-hemoptysis-initial-experience-in-advanced-primary-lung-cancer-patients
#14
Akihiko Seki, Chigusa Shimono
PURPOSE: To evaluate the hemostatic effects of transarterial infusion chemotherapy in addition to embolization (chemoembolization) for advanced primary lung cancer with tumor-related hemoptysis. MATERIALS AND METHODS: Ten consecutive patients with stage IIIB/IV or recurrent primary lung cancer (squamous cell carcinoma in six, adenocarcinoma in four) who underwent chemoembolization for control of hemoptysis were enrolled. At enrollment, five patients were considered refractory and five had contraindications to standard therapies...
June 12, 2017: Japanese Journal of Radiology
https://www.readbyqxmd.com/read/28605745/current-standard-and-future-perspectives-in-non-surgical-therapy-for-hepatocellular-carcinoma
#15
Tobias Eggert, Tim F Greten
BACKGROUND: Hepatocellular carcinoma (HCC) is an aggressive liver tumor with a poor 5-year survival rate. Many HCCs are not amenable to surgical resection, because of tumor size, location, or because of the patient's poor liver function, a common obstacle to HCC therapy, because HCCs almost always develop in chronically inflamed livers. SUMMARY: In recent years, many efforts have been made to improve patient survival by conducting clinical trials investigating local and systemic treatment options for patients with unresectable tumors...
June 13, 2017: Digestion
https://www.readbyqxmd.com/read/28605614/medical-management-of-hepatocellular-carcinoma
#16
Nicole E Rich, Adam C Yopp, Amit G Singal
Hepatocellular carcinoma (HCC) typically occurs in patients with advanced liver disease, so therapeutic decisions must account for the degree of underlying liver dysfunction and patient performance status in addition to tumor burden. Curative treatment options, including liver transplantation, surgical resection, and local ablative therapies, offer 5-year survival rates exceeding 60% but are restricted to patients with early-stage HCC. Surgical resection and local ablative therapies are also limited by high recurrence rates, highlighting a need for adjuvant and/or neoadjuvant therapies...
June 2017: Journal of Oncology Practice
https://www.readbyqxmd.com/read/28603426/efficacy-and-safety-of-tace-in-combination-with-sorafenib-for-the-treatment-of-tace-refractory-advanced-hepatocellular-carcinoma-in-chinese-patients-a-retrospective-study
#17
Jianbing Wu, An Li, Jiajin Yang, Yanjun Lu, Jie Li
BACKGROUND: Transarterial chemoembolization (TACE) and sorafenib (SOR) are well-established treatments for hepatocellular carcinoma (HCC). This study evaluates the efficacy and safety of SOR combined with TACE in the treatment of patients with TACE-refractory, advanced-stage HCC. METHODS: This retrospective study included 61 patients with TACE-refractory advanced HCC. Patients were divided into TACE + SOR (n=30) and TACE (n=31) treatment groups. Patient demographic and clinical characteristics, overall survival (OS), time to progression (TTP), disease control rate (DCR), and adverse events (AEs) were compared between the two groups...
2017: OncoTargets and Therapy
https://www.readbyqxmd.com/read/28602057/body-composition-predicts-survival-in-patients-with-hepatocellular-carcinoma-treated-with-transarterial-chemoembolization
#18
Neehar D Parikh, Peng Zhang, Amit G Singal, Brian A Derstine, Venkat Krishnamurthy, Pranab Barman, Akbar K Waljee, Grace L Su
Purpose: The prognosis of patients with hepatocellular carcinoma (HCC) undergoing transarterial chemoembolization (TACE) is often uncertain. We aimed to utilize analytic morphomics, a high-throughput imaging analysis, to assess if body composition is predictive of post-TACE survival. Materials and Methods: We included patients from a single center (Ann Arbor VA) who had TACE as the primary treatment for HCC and had a pre-treatment CT scans. Univariate analysis and multivariate conditional inference tree analysis were utilized to identify the morphomic characteristics predictive of one-year survival...
June 1, 2017: Cancer Research and Treatment: Official Journal of Korean Cancer Association
https://www.readbyqxmd.com/read/28589145/metastasis-associated-protein-1-is-involved-in-angiogenesis-after-transarterial-chemoembolization-treatment
#19
Tao Xue, Wenming Feng, Hongbin Yu, Ming Zhu, Maoyun Fei, Ying Bao, Xiaoyi Wang, Wenxue Ma, Guiyuan Lv, Jianming Guan, Suhong Chen
BACKGROUND: Transarterial chemoembolization (TACE), a well-established treatment for unresectable hepatocellular carcinoma (HCC), blocks the arterial blood supply to the tumor, which can be short-lived as development of collateral neovessels, leading to the failure of treatment. Metastasis-associated protein 1 (MTA1) is involved in development of tumors and metastases. However, the role of MTA1 in angiogenesis is still obscure. METHODS: We detected the expression of MTA1 and hypoxia-inducible factor-1α (HIF-1α) and microvessel density (MVD) value in liver tumor tissues and tumor periphery before and after TACE treatment...
2017: BioMed Research International
https://www.readbyqxmd.com/read/28588882/transarterial-chemoembolization-vs-bland-embolization-in-hepatocellular-carcinoma-a-meta-analysis-of-randomized-trials
#20
Antonio Facciorusso, Francesco Bellanti, Rosanna Villani, Veronica Salvatore, Nicola Muscatiello, Fabio Piscaglia, Gianluigi Vendemiale, Gaetano Serviddio
BACKGROUND: Although transarterial chemoembolization is considered the standard of care for intermediate hepatocellular carcinoma patients, robust data in favor of a clear superiority of chemoembolization (with chemotherapy injection) over bland embolization are lacking. OBJECTIVE: The objective of this article is to systematically analyze the results provided by randomized controlled trials comparing these two treatments in hepatocarcinoma patients. METHODS: A computerized bibliographic search on the main databases was performed...
June 2017: United European Gastroenterology Journal
keyword
keyword
37760
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"